This English translation is AI-generated and provided for reference only.
中國社會

Navigating Tensions in China's Centralized Drug Procurement
如何從公司運作洞察關於集採的爭議

Amidst public concerns over drug efficacy, China's healthcare system faces scrutiny as doctors and regulatory bodies clash over centralized procurement practices. The debate highlights inherent tensions between cost control and quality assurance, underscoring the need for balanced oversight in healthcare policy.
劉遠舉:醫生說藥不好,醫保部門說藥好,在有限的資訊下,普通人該如何理解其中的爭議呢?

In response to claims that drugs from centralized procurement are ineffective, such as "blood pressure not lowering" and "anesthetics not working," the National Healthcare Security Administration recently issued a new statement. While it's good to have a response, this one came too quickly and doesn't match the amount of work required. Moreover, it lacks traceable, real-name endorsements, and even the journalist conducting the interview wasn't named. Therefore, further responses to public concerns are indeed necessary.

針對集採藥「血壓不降、麻藥不睡」等說法,國家醫保局近日給出了最新回應。有回應很好,但這個回應太快,與其需要的工作量不相符。而且缺乏可追溯的實名背書,連採訪的記者都沒署名。所以的確還需要進一步回應公衆關切。

您已閱讀5%(626字),剩餘95%(11608字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×